Clinical Trial Update: P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 trial of above-label octreotide LAR for insufficiently controlled carcinoid syndrome in neuroendocrine carcinoma was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Syndrome
• Neuroendocrine Carcinoma

Drugs mentioned

• Sandostatin LAR (octreotide)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Neuroendocrine Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2015-01-12